Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment

LIU Xuting; GAO Shengnan; QI Ran; DU Guiping; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2022.24.19

您当前的位置：

首页 >

文章列表页 >

Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment

更新时间：2025-09-26

- Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment
- ZHONGGUO YAOFANG Vol. 33, Issue 24, Pages: 3040-3044(2022)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.24.19
  CLC： R969.3;R556.3
- Received：14 July 2022，
  
  Revised：2022-11-16，
  
  Published：30 December 2022
- 稿件说明：
移动端阅览
刘旭婷,高胜男,齐冉,等.异麦芽糖酐铁治疗缺铁性贫血的快速卫生技术评估[J].中国药房,2022,33(24):3040-3044.

LIU Xuting,GAO Shengnan,QI Ran,et al.Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment[J].ZHONGGUO YAOFANG,2022,33(24):3040-3044.
刘旭婷,高胜男,齐冉,等.异麦芽糖酐铁治疗缺铁性贫血的快速卫生技术评估[J].中国药房,2022,33(24):3040-3044. DOI： 10.6039/j.issn.1001-0408.2022.24.19.

LIU Xuting,GAO Shengnan,QI Ran,et al.Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment[J].ZHONGGUO YAOFANG,2022,33(24):3040-3044. DOI： 10.6039/j.issn.1001-0408.2022.24.19.

摘要

目的

采用快速卫生技术评估（HTA）的方法评价异麦芽糖酐铁治疗缺铁性贫血的有效性、安全性和经济性，为临床决策提供循证依据。

方法

系统检索PubMed、Embase、Cochrane Library、中国知网、万方数据库和国外HTA官方网站，检索时限均为建库起至2022年5月25日。按照纳入排除标准对文献进行资料提取、质量评价后，对异麦芽糖酐铁治疗缺铁性贫血的有效性、安全性和经济性进行描述性分析。结果与

结论

共纳入1篇HTA报告、3篇系统评价/Meta分析和5篇经济学研究。在有效性方面，与羧基麦芽糖铁相比，使用异麦芽糖酐铁患者的血红蛋白水平提高更多，但二者的应答患者比例比较，差异无统计学意义；与蔗糖铁比较，异麦芽糖酐铁在增加和维持血红蛋白方面具有非劣效性，2组患者生活质量比较差异无统计学意义。在安全性方面，羧基麦芽糖铁、蔗糖铁和异麦芽糖酐铁的不良事件发生率分别为12.0%、15.3%、17.0%；异麦芽糖酐铁相比羧基麦芽糖铁的低磷血症发生率更低，相比蔗糖铁、右旋糖酐铁、纳米氧化铁的低磷血症发生率则差异无统计学意义；在治疗紧急不良事件发生率、严重不良事件发生率和患者因不良事件退出率方面，目前尚无确切结论。在经济性方面，异麦芽糖酐铁的经济性优于蔗糖铁，而对比羧基麦芽糖铁的经济性尚未有定论。

Abstract

OBJECTIVE

To evaluate the effectiveness， safety and economy of iron isomaltoside in the treatment of iron deficiency anemia using a rapid health technology assessment （HTA） method， and provide an evidence-based basis for clinical decision-making.

METHODS

PubMed， Embase， Cochrane Library， CNKI， Wanfang database and foreign HTA official websites were systematically searched， and the search time frame of the databases was from the establishment of the database to May 25th 2022. After data extraction and quality evaluation of the literature according to the inclusion and exclusion criteria， a descriptive analysis of the effectiveness， safety and economy of iron isomaltoside in the treatment of iron deficiency anemia was performed.RESULTS &

CONCLUSIONS

A total of 1 HTA report， 3 systematic reviews/meta-analysis and 5 economic studies were included. In terms of effectiveness， compared with ferric carboxymaltose， the hemoglobin level of patients using iron isomaltoside increased more， but there was no significant difference in the proportion of responding patients； compared with iron sucrose， it had non-inferiority in increasing and maintaining hemoglobin level， and there was no difference in the quality of life. In terms of safety， the incidence of adverse events of ferric carboxymaltose， iron sucrose and iron isomaltoside were 12.0%， 15.3% and 17.0%， respectively. Iron isomaltoside had a lower incidence of hypophosphatemia， compared with ferric carboxymaltose. There was no statistical difference in the incidence of hypophosphatemia among iron isomaltoside， iron sucrose， iron-dextrin and nanocrystalline iron oxide. The conclusion of the incidence of treatment-emergent adverse event， the incidence of serious adverse events and the withdrawal rate of patients due to adverse events was not clear. In terms of economy， the economy of iron isomaltoside is better than that of iron sucrose， and the economy of iron isomaltoside versus that of ferric carboxymaltose had not been finalized.

关键词

Keywords

references

JIMENEZ K ， KULNIGG-DABSCH S ， GASCHE C . Management of iron deficiency anemia [J ] . Gastroenterol Hepatol（NY）， 2015 ， 11 （ 4 ）： 241 - 250 .

CALDRER S ， URSINI T ， SANTUCCI B ， et al . Soil-transmitted helminths and anaemia：a neglected association outside the tropics [J ] . Microorganisms ， 2022 ， 10 （ 5 ）： 1027 .

ABOMHYA A ， TAI W ， AYAZ S ， et al . Iron deficiency anemia：an overlooked complication of Crohn’s disease [J ] . J Hematol ， 2022 ， 11 （ 2 ）： 55 - 61 .

中华医学会血液学分会红细胞疾病（贫血）学组 . 静脉铁剂应用中国专家共识：2019年版 [J ] . 中华血液学杂志， 2019 ， 40 （ 5 ）： 358 - 362 .

CAMASCHELLA C . Iron-deficiency anemia [J ] . N Engl J Med ， 2015 ， 372 （ 19 ）： 1832 - 1843 .

解玥，张弨 . 异麦芽糖酐铁、蔗糖铁和低分子右旋糖酐铁的临床价值比较 [J ] . 临床药物治疗杂志， 2021 ， 19 （ 8 ）： 29 - 33 .

RUND D . Intravenous iron：do we adequately understand the short- and long-term risks in clinical practice? [J ] . Br J Haematol ， 2021 ， 193 （ 3 ）： 466 - 480 .

KALRA P A ， BHANDARI S ， SPYRIDON M ， et al . NIMO-CKD-UK：a real-world，observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease [J ] . BMC Nephrol ， 2020 ， 21 （ 1 ）： 539 .

刘梦娜，吴斌，艾丹丹，等 . 药物快速卫生技术评估方法学研究：以抗肿瘤用药为例 [J ] . 中国药房， 2022 ， 33 （ 11 ）： 1386 - 1391 .

HAILEY D . Toward transparency in health technology assessment：a checklist for HTA reports [J ] . Int J Technol Assess Health Care ， 2003 ， 19 （ 1 ）： 1 - 7 .

张方圆，沈傲梅，曾宪涛，等 . 系统评价方法学质量评价工具AMSTAR 2解读 [J ] . 中国循证心血管医学杂志， 2018 ， 10 （ 1 ）： 14 - 18 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated health economic evaluation reporting standards 2022（CHEERS 2022）statement：updated repor-ting guidance for health economic evaluations [J ] . Value Health ， 2022 ， 25 （ 1 ）： 3 - 9 .

Canada CADTH . Iron（Ⅲ） isomaltoside 1 000 [EB/OL ] .（ 2020-05-29 ）[ 2022-05-25 ] . https：//www.cadth.ca/iron-iii-isomaltoside-1000 https://www.cadth.ca/iron-iii-isomaltoside-1000 .

POLLOCK R F ， MUDUMA G . A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment [J ] . Expert Rev Hematol ， 2019 ， 12 （ 2 ）： 129 - 136 .

AKSAN A ， IŞıK H ， RADEKE H H ， et al . Systematic review with network meta-analysis：comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease [J ] . Aliment Pharmacol Ther ， 2017 ， 45 （ 10 ）： 1303 - 1318 .

BELLOS I ， FROUNTZAS M ， PERGIALIOTIS V . Comparative risk of hypophosphatemia following the admini-stration of intravenous iron formulations：a network meta-analysis [J ] . Transfus Med Rev ， 2020 ， 34 （ 3 ）： 188 - 194 .

POLLOCK R F ， MUDUMA G . A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom [J ] . J Med Econ ， 2020 ， 23 （ 7 ）： 751 - 759 .

AKSAN A ， BEALES I L P ， BAXTER G ， et al . Evaluation of the cost-effectiveness of iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease in the UK [J ] . Clinicoecon Outcomes Res ， 2021 ， 13 ： 541 - 552 .

HU S L ， LIU L M ， POLLOCK R F ， et al . Intravenous iron for the treatment of iron deficiency anemia in China：a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose [J ] . J Med Econ ， 2022 ， 25 （ 1 ）： 561 - 570 .

AKSAN A ， SCHOEPFER A ， JUILLERAT P ， et al . Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease：a cost-effectiveness analysis in Switzerland [J ] . Adv Ther ， 2021 ， 38 （ 1 ）： 660 - 677 .

BHANDARI S . Update of a comparative analysis of cost minimization following the introduction of newly avai- lable intravenous iron therapies in hospital practice [J ] . Ther Clin Risk Manag ， 2011 ， 7 ： 501 - 509 .

沈晶晶，徐永灿，陈叶龙 . 成人缺铁性贫血患者消化道肿瘤的危险因素分析 [J ] . 中国现代医生， 2022 ， 60 （ 5 ）： 105 - 108 .

肖若薇，李薇，孙文韬，等 . 使用静脉铁剂的住院患者贫血治疗现状真实世界研究 [J ] . 临床药物治疗杂志， 2022 ， 20 （ 6 ）： 67 - 71 .

李莉娟，张连生 . 缺铁性贫血规范化诊治的若干问题 [J ] . 中华医学杂志， 2021 ， 101 （ 40 ）： 3266 - 3270 .

Views

325

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer

Apixaban for the prevention and treatment of cancer-associated venous thromboembolism： a rapid health technology assessment

Rapid health technology assessment of tirzepatide for diabetes mellitus type 2 and long-term weight management

Calcium channel modulators in the treatment of diabetic peripheral neuropathic pain： a rapid health technology assessment

Rapid health technology assessment of the efficacy， safety and cost-effectiveness of vericiguat in the treatment of heart failure

Related Author

LIU Huanlong

NIE Ying

WANG Xiaohui

GONG Yuan

KANG Shuo

HOU Yibing

WANG Huayu

SHANGGUAN Keke

Related Institution

School of Pharmacy， Hebei Medical University

Medical Insurance Office， the Second Hospital of Hebei Medical University

Dept. of Pharmacy， the Second Hospital of Hebei Medical University

Dept. of Vascular Surgery， the Second Hospital of Tianjin Medical University

Dept. of Pharmacy，the Second Hospital of Tianjin Medical University

⁰